MaaT013,ruxolitinib
MaaT Pharma,novartis,incyte
['ruxolitinib', 'rux,(-crux),(-trux)', 'rux,(-crux),(-trux),(-deruxtecan)']
#ash22
abstract 112 presenting the results of the pooled allogeneic microbiotherapy maat013 early access program in france. maat013 is highly effective therapy for s- and sd-gi- agvhd excellent responses in the ruxolitinib-refractory patients response = os 
Hematologist at Saint Antoine Hospital, Paris, France @Sorbonne_Univ_ @APHP. @JACIE_EBMT National Representative. #BMTsm #LYMsm #CARTcell #CardioOnc #QoL